Publications

Hu J = me · # co-first author · * corresponding author. Also on Google Scholar, PubMed, and ORCID.

Selected

  1. Li YR, Hu J#, Li Z, Zhu E, Chen Y, … Wu L, Yang L. Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells. Cell Rep Med 2025;6(9).
  2. Hu J, Tan P, Ishihara M, Bayley NA, Schokrpur S, … Xu H, Wu L. Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma. Signal Transduct Target Ther 2023;8(1):155.
  3. Hu J, Guan W, Liu P, Dai J, Tang K, … Wu L, Xu H. Endoglin is essential for the maintenance of self-renewal and chemoresistance in renal cancer stem cells. Stem Cell Reports 2017;9(2):464-477.

Peer-reviewed articles

2025

  1. Li YR, Hu J#, Li Z, Zhu E, Chen Y, … Wu L, Yang L. Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells. Cell Rep Med 2025;6(9).

2023

  1. Flora K, Ishihara M, Zhang Z, … Hu J*, Wu L. Exosomes from von Hippel-Lindau-null cancer cells promote metastasis in renal cell carcinoma. Int J Mol Sci 2023;24(24):17307.
  2. Hu J*, Smith DJ, Wu L. VHL L169P variant does not alter cellular hypoxia tension in clear cell renal cell carcinoma. Int J Mol Sci 2023;24(18):14075.
  3. Hu J, Tan P, Ishihara M, Bayley NA, Schokrpur S, … Xu H, Wu L. Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma. Signal Transduct Target Ther 2023;8(1):155.
  4. Sun N, Zhang C, Lee YT, … Hu J, … Tseng HR, Zhu Y. HCC EV ECG score: an extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma. Hepatology 2023;77(3):774-788.

2022

  1. Zhang Z, Hu J, Ishihara M, Sharrow AC, Flora K, He Y, Wu L. The miRNA-21-5p payload in exosomes from M2 macrophages drives tumor cell aggression via PTEN/Akt signaling in renal cell carcinoma. Int J Mol Sci 2022;23(6):3005.

2021

  1. Zhang Z, Ai G, Chen L, … Hu J*, Huang J. Associations of immunological features with COVID-19 severity: a systematic review and meta-analysis. BMC Infect Dis 2021;21(1):738.
  2. Gao M, Wu H, Plamthottam R, Xie Z, Liu Y, Hu J, Wu S, Wu L, He X, Pei Q. Skin temperature-triggered, debonding-on-demand sticker for a self-powered mechanosensitive communication system. Matter 2021;4(6):1962-1974.
  3. Guan W, Li F, Zhao Z, Zhang Z, Hu J, Zhang Y. Tumor-associated macrophage promotes the survival of cancer cells upon docetaxel chemotherapy via the CSF1/CSF1R–CXCL12/CXCR4 axis in castration-resistant prostate cancer. Genes 2021;12(5):773.
  4. Zeng J, Xu H, Huang C, … Hu J, … Ye Z, Chen K. CD46 splice variant enhances translation of specific mRNAs linked to an aggressive tumor cell phenotype in bladder cancer. Mol Ther Nucleic Acids 2021;24:140-153.
  5. Chen K, Zeng J, Sun Y, … Hu J, … Ye Z, Xu H. Junction plakoglobin regulates and destabilizes HIF2α to inhibit tumorigenesis of renal cell carcinoma. Cancer Commun 2021;41(4):316-332.

2020

  1. Dong J, Zhang RY, Sun N, Hu J, … Tseng HR, Zhu Y. Coupling nanostructured microchips with covalent chemistry enables purification of sarcoma-derived extracellular vesicles for downstream functional studies. Adv Funct Mater 2020;30(49):2003237.
  2. Ishihara M, Hu J#, Zhang X, Choi YH, Wong A, Cano-Ruiz C, Zhao R, Tan P, Tso J, Wu L. Comparing metastatic clear cell renal cell carcinoma model established in mouse kidney and on chicken chorioallantoic membrane. J Vis Exp 2020;(156):e60314.
  3. Sharrow AC, Ishihara M, Hu J, Kim IH, Wu L. Using the chicken chorioallantoic membrane in vivo model to study gynecological and urological cancers. J Vis Exp 2020;(155):e60651.

2019

  1. Yan L, Ding B, Liu H, … Hu J, … Wu L, Xu H. Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma. Theranostics 2019;9(26):8377-8391.
  2. Hu J, Ishihara M, Chin AI, Wu L. Establishment of xenografts of urological cancers on chicken chorioallantoic membrane (CAM) to study metastasis. Precis Clin Med 2019;2(3):140-151.
  3. Zhou H, Tang K, Liu H, … Hu J, … Xu H, Ye Z. Regulatory network of two tumor-suppressive noncoding RNAs interferes with the growth and metastasis of renal cell carcinoma. Mol Ther Nucleic Acids 2019;16:554-565.
  4. Hu J, Guan W, Yan L, Ye Z, Wu L, Xu H. Cancer stem cell marker endoglin (CD105) induces epithelial mesenchymal transition (EMT) but not metastasis in clear cell renal cell carcinoma. Stem Cells Int 2019;2019:9060152.
  5. Guan W, Hu J#, Yang L, Tan P, Tang Z, West BL, Bollag G, Xu H, Wu L. Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancer. Endocr Relat Cancer 2019;26(1):131-140.

2018

  1. Hu J, Schokrpur S, Archang M, Hermann K, Sharrow AC, … Xu H, Wu L. A non-integrating lentiviral approach overcomes Cas9-induced immune rejection to establish an immunocompetent metastatic renal cancer model. Mol Ther Methods Clin Dev 2018;9:203-210.

2017

  1. Hu J, Guan W, Liu P, Dai J, Tang K, … Wu L, Xu H. Endoglin is essential for the maintenance of self-renewal and chemoresistance in renal cancer stem cells. Stem Cell Reports 2017;9(2):464-477.
  2. Yang T, Zhou H, Liu P, … Hu J, … Ye Z. lncRNA PVT1 and its splicing variant function as competing endogenous RNA to regulate clear cell renal cell carcinoma progression. Oncotarget 2017;8(49):85353-85367.
  3. Chen K, Xiao H, Zeng J, … Hu J, … Xu H, Ye Z. Alternative splicing of EZH2 pre-mRNA by SF3B3 contributes to the tumorigenic potential of renal cancer. Clin Cancer Res 2017;23(13):3428-3441.

2016

  1. Schokrpur S, Hu J, Moughon DL, Liu P, Lin LC, … Xu H. CRISPR-mediated VHL knockout generates an improved model for metastatic renal cell carcinoma. Sci Rep 2016;6:29032.
  2. Chen K, Zeng J, Xiao H, Huang C, Hu J, … Xu H, Ye Z. Regulation of glucose metabolism by p62/SQSTM1 through HIF1α. J Cell Sci 2016;129(4):817-830.
  3. Chen K, Zeng J, Tang K, Xiao H, Hu J, … Guan W. miR-490-5p suppresses tumour growth in renal cell carcinoma through targeting PIK3CA. Biol Cell 2016;108(2):41-50.

2015

  1. Xiao H, Tang K, Liu P, Chen K, Hu J, … Xu H, Huang Q. LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma. Oncotarget 2015;6(35):38005-38015.
  2. Xiao H, Zeng J, Li H, Chen K, Yu G, Hu J, … Ye Z. MiR-1 downregulation correlates with poor survival in clear cell renal cell carcinoma where it interferes with cell cycle regulation and metastasis. Oncotarget 2015;6(15):13201-13215.

2014

  1. Yu G, Li H, Wang J, … Hu J, Xiao H. miRNA-34a suppresses cell proliferation and metastasis by targeting CD44 in human renal carcinoma cells. J Urol 2014;192(4):1229-1237.
  2. Xiao H, Li H, Yu G, Xiao W, Hu J, … Ye Z. MicroRNA-10b promotes migration and invasion through KLF4 and HOXD10 in human bladder cancer. Oncol Rep 2014;31(4):1832-1838.

Book chapter and review

  1. Ishihara M, Hu J, Wong A, Cano-Ruiz C, Wu L. Mouse- and patient-derived CAM xenografts for studying metastatic renal cell carcinoma. In: Tamanoi F, ed. The Enzymes, vol. 46. Academic Press; 2019:59-80.
  2. Hu J, Ye Z. Present situation and the look into the future of experimental research in renal cancer. Chin J Exp Surg 2013;30(6):1107-1109. (In Chinese.)

Conference abstracts

  1. Wu L, Hu J, Ishihara M, Brodie G, Siltari A, Kim J, Conway S, …. Older statins reduce metastatic potential in ccRCC: mechanistic validation of SIM (selective inhibitor of metastasis) development. Cancer Res 2026;86(7 Suppl):7308.
  2. Kim J, Shams S, Vaca D, Hu J, Ishihara M, Threets K, Damoiseaux R, …. Assessing statin sensitivity and hypoxia regulation in aggressive metastatic cancers. Cancer Res 2026;86(7 Suppl):3162.
  3. Li Y, Hu J, Yang L, Wu L, Chin AI. Allogeneic HSPC-engineered CD70-directed CAR-NKT cells for renal cell carcinoma targeting tumor, microenvironment, and alloreactive T cells. Oncologist 2025;30(Suppl 2).
  4. Ishihara M, Hu J, Brodie G, Bowen E, Shams S, Vaca D, Kim J, Conway S, …. Statin-derived small-molecule inhibitors of metastasis (SIM) for high-risk epithelial cancers. Cancer Res 2025;85(8 Suppl 1):4248.
  5. Hu J, Tan P, Ishihara M, … Xu H, Wu L. Intratumoral heterogeneity of VHL and HIF1α drives lung metastasis in ccRCC. Kidney Cancer Research Summit, Boston 2023.
  6. Ishihara M, Hu J, Cano-Ruiz C, Jackson M, Wu A, Conway S, Damoiseaux R, Wu L. Statins inhibit the collaborative metastasis mediated by VHL heterogeneity in clear cell renal cell carcinoma (ccRCC) via a non-cholesterol pathway. Cancer Res 2023;83(7 Suppl):1611.
  7. Ishihara M, Hu J, Cano-Ruiz C, Wong A, Wu L. Using the chicken chorioallantoic membrane in vivo model to study metastatic kidney cancer: a novel drug screening approach with more sustainable patient-derived xenografts. Cancer Res 2020;80(16 Suppl):6121.

Patent applications

  1. Wu L, Hu J, Ishihara M, Damoiseaux R, Brodie G, Conway S. Methods and compositions for inhibiting metastasis of solid tumors. International patent application, 2024.
  2. Wu L, Hu J, Ishihara M, Damoiseaux R, Conway S. Compounds and methods for inhibiting metastasis of solid tumors. International patent application, 2024.
  3. Wu L, Damoiseaux R, Ishihara M, Hu J. Methods and compositions for inhibiting metastasis of solid tumors. US patent application, 2023.
  4. Wu L, Hu J, Schokrpur S. Methods and compositions for inhibiting periostin-mediated metastatic renal cell carcinoma. US patent application, 2019.